Abstract:Epilepsy Currents, Ahead of Print. Empiric Dosing Strategies to Predict Lamotrigine Concentrations During Pregnancy Barry JM, French JA, Pennell PB, Karanam A, Harden CL, Birnbaum AK. Pharmacotherapy. 2023;43(10):998-1006. doi:10.1002/phar.2856. PMID: 37475496 Introduction:Maintaining seizure control with lamotrigine is complicated by altered pharmacokinetics and existence of subpopulations in whom clearance increases or remains constant during pregnancy.Objective:Our objective was to characterize the potential for particular dosing scenarios to lead to increased seizure risk or toxicity.Methods:Lamotrigine pharmacokinetic parameters obtained from our previous study were applied to a one-compartment model structure with subpopulations (75:25%) exhibiting different clearance changes. A single-patient simulation was conducted with typical pharmacokinetic parameter values from each subpopulation. Population-level simulations (N = 48,000) included six dosing scenarios and considered four preconception doses using the R package mrgsolve (Metrum Research Group). Thresholds for efficacy and toxicity were selected as drug concentration that are 65% lower than preconception concentrations and doubling of preconception concentrations, respectively.Results:Individual simulation results demonstrated that without dose increases, concentrations fell below 0.65 at 6-8 weeks in the high clearance change (HC) subpopulation, depending on preconception clearance. While no simulated dosing regimen allowed all women in both subpopulations to maintain preconception concentrations, some regimens provided a more balanced risk profile than others. Predicted concentrations suggested potential increased seizure risk for 7%-100% of women in the HC group depending on preconception dose and subpopulation. Additionally, in 63% of dosing scenarios for women with low clearance change (LC), there was an increased risk of toxicity (34%-100% of women).Significance:A substantial percentage of simulated individuals had concentrations low enough to potentially increase seizure risk or high enough to create toxicity. Early clearance changes indicate possible subpopulation categorization if therapeutic drug monitoring is conducted in the first trimester. An arbitrary "one-size-fits-all" philosophy may not work well for lamotrigine dosing adjustments during pregnancy and reinforces the need for therapeutic drug monitoring until a patient is determined to be in the LC or HC group.

Dose-dependent effect of lamotrigine on quetiapine serum concentration in patients using instant release tablets

Pharmacokinetic interaction of quetiapine and lamotrigine – victim and perpetrator?

The Impact of Quetiapine Monotherapy or in Combination with Lithium on the Thyroid Function in Patients with Bipolar Depression: A Retrospective Study

Ethosuximide lowers lamotrigine serum concentrations: Evidence for a clinically relevant interaction

Metabolic Mechanism of Quetiapine at Clinical Therapeutic Dose in Vivo

Effect of Oral Contraceptives on Lamotrigine Levels Depends on Comedication.

Effect of Genetic Polymorphisms of ABCB1, ABCG2, and SLC22A1 on the Steady-State Plasma Concentrations of Lamotrigine in Treatment-Resistant Depressed Patients Treated With Lamotrigine Augmentation Therapy

Doses, serum concentrations and diagnoses of Norwegian quetiapine users 2001–2019 in a therapeutic drug monitoring material

Effect of Erythromycin on Metabolism of Quetiapine in Chinese Suffering from Schizophrenia

Acute Quetiapine Intoxication: Relationship Between Ingested Dose, Serum Concentration and Clinical Presentation-Structured Literature Review and Analysis

Distribution of quetiapine between serum and whole blood in therapeutic drug monitoring specimens

Dose Monitoring of Lamotrigine Monotherapy in Pregnancy: Are Pregnant Women with Epilepsy Currently Optimally Managed? A Systematic Review

Step Climb Dosing Guidance From Simulation Studies on Lamotrigine Concentration Changes During Pregnancy

Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters

Specific OCT1 and ABCG2 Polymorphisms Are Associated with Lamotrigine Concentrations in Chinese Patients with Epilepsy

Lamotrigine Therapy for Bipolar Depression: Analysis of Self-Reported Patient Data

An LC-MS/MS Method for Quantification of Lamotrigine and Its Main Metabolite in Dried Blood Spots

The Study for the Relation Between the Serum Concentration of Lamotrigine and its Effect

EFFICACY AND TOLERABILITY OF QUETIAPINE XR 400/600/800MG/DAY IN ACUTE SCHIZOPHRENIA: A POST-HOC ANALYSIS OF DATA FROM TWO POOLED RANDOMISED STUDIES

An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS)-based candidate reference measurement procedure (RMP) for the quantification of lamotrigine in human serum and plasma

Pharmacokinetics and Safety of Atogepant Co‐administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open‐Label, Drug‐Drug Interaction Study